Securing Funding for Psychedelic Therapy: A Milestone for ATAI Life Sciences (NASDAQ:ATAI) and Clearmind Medicine (NASDAQ:CMND)
A major milestone was reached by the Multidisciplinary Association for Psychedelic Studies (MAPS) Public Benefit Corporation, a key player in the psychedelics industry. The corporation has secured over $100 million in a Series A private stock sale, marking a decade of progress since its establishment as a subsidiary of MAPS. This funding is intended to bolster the organization’s final steps toward gaining regulatory approval to utilize MDMA, commonly known as ecstasy, for treating post-traumatic stress disorder (PTSD).
MAPS has made significant strides in the field of psychedelic-assisted therapy research, culminating in the submission of a New Drug Application to the FDA following successful completion of two Phase 3 studies.
Moving Psychedelic Research to New Heights: VA Funding for Treating PTSD and Depression in Military Veterans
In a bold move, the U.S. Department of Veterans Affairs (VA) has initiated new studies focusing on the use of psychedelic compounds to address PTSD and depression in military veterans. This marks a pivotal step for the VA, representing the first time such research has been conducted since the 1960s. The VA’s latest effort will further explore the effectiveness and safety of MDMA and psilocybin-augmented psychotherapy in veterans, underscoring a significant shift in the agency’s approach to mental health treatment.
Spotlight on Key Influencers: Identifying Pioneers in the Psychedelics Industry
The global movement surrounding psychedelic medicines has been propelled by influential figures hailing from diverse backgrounds, including scientists, investors, advocates, publicists, journalists, and policy reformers. Industries across various countries and companies have been part of this transformative journey, highlighting the global impact of psychedelic therapy on mental health.
Policy Reforms in the Psychedelics Landscape: A State-Level Overview
Paralleling recent federal decisions by President Biden and the VA, state-level psychedelics policy reform has seen rapid progress across the country. As of Jan. 9, 2024, multiple states, including Arizona, California, Illinois, Indiana, Massachusetts, Missouri, Nevada, New Hampshire, New York, Rhode Island, Virginia, Washington, and Wisconsin, are advancing policies related to psychedelics. Additionally, Ypsilanti in Michigan has become the fifth city in the state to decriminalize psychedelics through a local resolution.
Market Performance: Insights into Psychedelics ETF and Top Trading Stocks
The AdvisorShares Psychedelics ETF (PSIL) has showcased fluctuations in its weekly performance, with opening and closing prices witnessing variations over the course of recent weeks. Notably, specific psychedelics stocks, such as COMPASS Pathways, GH Research, Incannex Healthcare, Mind Medicine (MindMed), ATAI Life Sciences, Bright Minds Biosciences, Silo Pharma, Seelos Therapeutics, Clearmind Medicine, and Enveric Biosciences, have experienced notable changes in their closing prices on Jan. 12, signifying the dynamic nature of the market.
Stock trading numbers above according to Benzinga Pro, our all-the-information-you-need streaming platform, helping you invest smarter – Come join us and see for yourself!
